HLB Announces Liver Cancer Treatment Results at ASCO

· HLB's US subsidiary Elevar Therapeutics announced the updated Phase 3 CARES-310 study for uHCC at ASCO 2024.

HLB Announces Promising Liver Cancer Treatment Results at ASCO 2024 (Credit: HLB)

SEOUL, South Korea, June 3, 2024 (IT Times) - HLB, a leading biopharmaceutical company, today announced that the updated Phase 3 CARES-310 study evaluating a novel combination therapy with rivoceranib in unresectable hepatocellular carcinoma (uHCC) was presented as a poster at the American Society of Clinical Oncology (ASCO) 2024 meeting in Chicago. The results generated significant interest, with experts gathering to discuss the drug's potential to become a new standard treatment for liver cancer.

Promising Survival Rates and Tolerability Profile

The updated results showed a remarkably extended median overall survival (mOS) of nearly two years (23.8 months) in patients treated with the rivoceranib combination, compared to 22.1 months previously reported. This represents an improvement of 8.6 months over sorafenib, the current standard first-line treatment for uHCC.

The treatment was also well-tolerated, with manageable treatment-related adverse events (TRAEs) such as hypertension. The discontinuation rate due to TRAEs was minimal at 4.4% in the rivoceranib arm, compared to 4.8% in the control group, highlighting a favorable benefit-risk profile.

Source - IT Times : https://www.ittimes.com/news/articleView.html?idxno=35413

HLB Announces Promising Liver Cancer Treatment Results at ASCO 2024 - IT타임스